5F9 will be tested in combination with rituximab and Calquence (acalabrutinib) for diffuse large B-cell lymphoma.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.